Lexeo Therapeutics, Inc. filed a Current Report on Form 8-K on November 16, 2026, announcing financial results for the three and nine months ended September 30, 2026, along with positive interim Phase I/II clinical data for its gene therapy candidate LX2020.

Key Highlights

  • Reporting period: Financial results cover the three and nine months ended September 30, 2026.
  • Clinical update: The company announced positive interim Phase I/II clinical data for LX2020, its candidate for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM).
  • Regulatory updates: The filing notes that regulatory updates for LX2020 were also included in the press release.
  • Conference call: A conference call and webcast was held at 8:00 a.m. ET on November 16, 2026, to discuss the LX2020 interim Phase I/II clinical data.
  • Corporate presentation: An updated corporate presentation was posted to the company's website on November 16, 2026, for use in meetings with investors and analysts.
  • Signed by: The report was signed by R. Nolan Townsend, Chief Executive Officer.

Lexeo Discloses LX2020 Interim Clinical Data Alongside Q3 2026 Financials

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a Delaware-incorporated biopharmaceutical company headquartered at 345 Park Avenue South, New York, New York 10010, filed a Current Report on Form 8-K on November 16, 2026, covering results of operations and financial condition under Item 2.02. According to the filing, the company issued a press release on that date announcing business highlights and financial results for the three and nine months ended September 30, 2026. The press release is furnished as Exhibit 99.1 and incorporated by reference.

Under Item 8.01, the filing disclosed that the same press release included positive interim Phase I/II clinical data and regulatory updates for LX2020, the company's candidate for the treatment of PKP2-associated arrhythmogenic cardiomyopathy, referred to in the filing as PKP2-ACM. The company disclosed it hosted a conference call and webcast at 8:00 a.m. ET on November 16, 2026, to discuss the LX2020 interim Phase I/II clinical data. An LX2020-specific corporate presentation dated November 16, 2026, is furnished as Exhibit 99.2.

Under Item 7.01, the filing disclosed a separate updated corporate presentation posted to the company's website on November 16, 2026, intended for use from time to time in meetings with investors and analysts. That presentation is attached as Exhibit 99.3. The filing notes that the information in Items 2.02 and 7.01, along with their associated exhibits, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section, except as expressly set forth by specific reference in a filing.

What Was Disclosed

Lexeo Therapeutics filed an 8-K on November 16, 2026, reporting Q3 2026 financial results, positive interim Phase I/II data and regulatory updates for LX2020 in PKP2-ACM, and the posting of updated corporate presentations for investor and analyst use.